(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentan-1-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentan-1-ol
• 化学式: C₃₃H₆₃N₃O₄
• 分子量: 565.9
• InChiKey: KJHKUNPRTTYLNC-HPEVASSUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  40
• 可旋转键数：
  16
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Methods for treating fungal infections
  申请人：Genberg Carl

  公开号：US10238665B2

  公开（公告）日：2019-03-26

  Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

  本文公开了治疗患者真菌感染的方法，包括确定需要治疗的患者并施用治疗有效量的至少一种阳离子类固醇抗菌剂（CSA）或其药学上可接受的盐。本文还考虑了包含此类组合物的试剂盒和此类方法的说明书。
• CATIONIC STEROIDAL ANTIMICROBIAL SALTS
  申请人：Savage Paul B.

  公开号：US20170174720A9

  公开（公告）日：2017-06-22

  Disclosed herein are acid addition salts of cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous salt forms are identified, such as 1,5-naphthalenedisulfonic acid addition salts and sulfate addition salts. The acid addition salts may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering acid addition salts of CSAs.
• METHODS FOR TREATING FUNGAL INFECTIONS
  申请人：Genberg Carl

  公开号：US20170232004A1

  公开（公告）日：2017-08-17

  Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.